GOLDEN, Colo. — May 19, 2026 — A growing emphasis on dose-sparing strategies and equitable vaccine access has renewed global interest in ID vaccine delivery. A recent, peer-reviewed publication in Qeios¹ evaluated the evidence on implementation of novel technologies for ID delivery of fractional-dose inactivated polio vaccine (fIPV).
View
GOLDEN, Colo. — May 7, 2026 — PharmaJet, a global leader in needle-free injection technology, today announced that its WHO-prequalified Tropis ID Needle-free Injection System will be used to deliver approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV) during upcoming polio immunization campaigns in Nigeria. PharmaJet is partnering
View
GOLDEN, Colo., CAIRO, Egypt — November 6, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Distribution Agreement with ATR, an affiliate to EVA Pharma, the leading pharmaceutical company driving healthcare
View
GOLDEN, Colo. — November 4, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, November 9-13, at the Metro Toronto Convention Centre in Toronto, Ontario,
View
PharmaJet® Tropis® Needle-free Injection System selected for Polio Immunization Campaign in Pakistan
GOLDEN, Colo. — October 23, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its innovative needle-free injection technology, today announced that their WHO prequalified Tropis ID Needle-free Injection System will be used in the latest polio immunization campaign in Pakistan, planned for
View
GOLDEN, Colo. — August 20, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan.
View
GOLDEN, Colo., CAIRO, Egypt — July 10, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma,
View
GOLDEN, Colo. — June 5, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that Vaccines has published the results of an implementation research study entitled Evaluating the impact of needle-free delivery of inactivated polio vaccine
View
GOLDEN, Colo. — May 1, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, today announced the publication of a study demonstrating the benefits of PharmaJet Tropis needle-free system compared with N/S for ID administration of fractional dose poliovirus
View
Load more